BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Feraheme (Ferumoxytol) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Feraheme (Ferumoxytol)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05340465-879@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Feraheme (Ferumoxytol): Phase 2 readout est. (NCT05340465)
DESCRIPTION:Feraheme (Ferumoxytol)\, phase 2\, Iron Deficiency Anemia.\nStu
 dy: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Suf
 ficiency in Preterm Infants\nEstimated primary completion: 30 January 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ferumoxytol#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05340465
URL:https://assetmemo.bio/drug/ferumoxytol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634640-879@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Feraheme (Ferumoxytol): Phase 1 readout est. (NCT07634640)
DESCRIPTION:Feraheme (Ferumoxytol)\, phase 1.\nStudy: Hearts on Fire: Targe
 ting Inflammation in Heart Failure With Preserved Ejection Fraction\nEstim
 ated primary completion: 31 May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ferumoxytol#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07634640
URL:https://assetmemo.bio/drug/ferumoxytol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06440408-879@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Feraheme (Ferumoxytol): Phase 1 readout est. (NCT06440408)
DESCRIPTION:Feraheme (Ferumoxytol)\, phase 1.\nStudy: Calculating Wall Shea
 r Stress in Infant Pulmonary Veins\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ferumoxytol#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06440408
URL:https://assetmemo.bio/drug/ferumoxytol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03270059-879@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Feraheme (Ferumoxytol): Phase 2 readout est. (NCT03270059)
DESCRIPTION:Feraheme (Ferumoxytol)\, phase 2.\nStudy: Gadolinium and Ferumo
 xytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous
  System\nEstimated primary completion: 15 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/ferumoxytol#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03270059
URL:https://assetmemo.bio/drug/ferumoxytol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04369560-879@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Feraheme (Ferumoxytol): Phase 1 readout est. (NCT04369560)
DESCRIPTION:Feraheme (Ferumoxytol)\, phase 1.\nStudy: Virtual Histology of 
 the Bladder Wall for Bladder Cancer Staging\nEstimated primary completion:
  30 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fer
 umoxytol#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04369560
URL:https://assetmemo.bio/drug/ferumoxytol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07461948-879@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20281027
DTEND;VALUE=DATE:20281028
SUMMARY:Feraheme (Ferumoxytol): Phase 3 readout est. (NCT07461948)
DESCRIPTION:Feraheme (Ferumoxytol)\, phase 3.\nStudy: Advanced Imaging Tech
 niques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Pa
 tients\nEstimated primary completion: 27 October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ferumoxytol#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07461948
URL:https://assetmemo.bio/drug/ferumoxytol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03649880-879@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Feraheme (Ferumoxytol): Phase 2 readout est. (NCT03649880)
DESCRIPTION:Feraheme (Ferumoxytol)\, phase 2.\nStudy: Feasibility of FMISO 
 in Brain Tumors\nEstimated primary completion: 31 January 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ferumoxytol#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT03649880
URL:https://assetmemo.bio/drug/ferumoxytol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483061-879@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Feraheme (Ferumoxytol): Phase 2 readout est. (NCT06483061)
DESCRIPTION:Feraheme (Ferumoxytol)\, phase 2.\nStudy: Enhanced MRI Imaging 
 in Healthy Participants and Participants With Epilepsy\nEstimated primary 
 completion: 1 September 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ferumoxytol#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06483061
URL:https://assetmemo.bio/drug/ferumoxytol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
